Daiwa Securities Group
FATE icon

Daiwa Securities Group’s Fate Therapeutics FATE Stock Holding History

Daiwa Securities Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-360
Closed -$1K – 1343
2023
Q3 		$1K Hold
360
– – ﹤0.01% 1250
2023
Q2 		$2K Hold
360
– – ﹤0.01% 1230
2023
Q1 		$2K Hold
360
– – ﹤0.01% 1213
2022
Q4 		$4K Hold
360
– – ﹤0.01% 1166
2022
Q3 		$8K Hold
360
– – ﹤0.01% 1138
2022
Q2 		$9K Buy
360
+81
+29% +$2.23K ﹤0.01% 1144
2022
Q1 		$11K Hold
279
– – ﹤0.01% 1135
2021
Q4 		$16K Sell
279
-47
-14% -$2.66K ﹤0.01% 1129
2021
Q3 		$19K Buy
326
+140
+75% +$11K ﹤0.01% 1107
2021
Q2 		$16K Hold
186
– – ﹤0.01% 1026
2021
Q1 		$15K Buy
186
+22
+13% +$2.11K ﹤0.01% 1023
2020
Q4 		$15K Sell
164
-326
-67% -$20.2K ﹤0.01% 994
2020
Q3 		$20K Buy
490
+80
+20% +$2.79K ﹤0.01% 991
2020
Q2 		$9K Hold
410
– – ﹤0.01% 1074
2020
Q1 		$9K Hold
410
– – ﹤0.01% 1065
2019
Q4 		$8K Hold
410
– – ﹤0.01% 1081
2019
Q3 		$6K Hold
410
– – ﹤0.01% 1065
2019
Q2 		$8K Hold
410
– – ﹤0.01% 1065
2019
Q1 		$7K Sell
410
-140
-25% -$2.21K ﹤0.01% 1054
2018
Q4 		$7K Buy
+550
New +$7.67K ﹤0.01% 1028

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Daiwa Securities Group's FATE Position: Q4 2023 in Review

Daiwa Securities Group sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 360 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in FATE in Q4 2018 and held it in 20 quarters. The position peaked at $20K in Q3 2020. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Daiwa Securities Group reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 360 Fate Therapeutics shares in Q4 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Fate Therapeutics in Q4 2018 and held it in 20 quarters.
  • Daiwa Securities Group's Fate Therapeutics position peaked at $20K in Q3 2020.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.